This is a working overview of Ac-LKKTETQ, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-03 and is reviewed periodically as new material appears.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
== C == Cadiot–Chodkiewicz coupling Cadogan-Sundberg indole synthesis Camps quinoline synthesis Cannizzaro reaction Carbohydrate acetalisation Carbonyl reduction Carbonylation Carbylamine reaction Carroll reaction Castro–Stephens coupling Catalytic reforming Catellani Reaction Corey–Itsuno reduction (AKA Corey–Bakshi–Shibata reduction or CBS reduction) Chan–Lam coupling Chapman rearrangement Cheletropic reaction Chichibabin pyridine synthesis Chichibabin reaction Chiral pool synthesis Chugaev elimination (also transliterated as Tschugajeff reaction) Ciamician–Dennstedt rearrangement Claisen condensation Claisen rearrangement Claisen–Schmidt condensation Clemmensen reduction Collins reagent Combes quinoline synthesis Conia reaction Conrad–Limpach synthesis Cook–Heilbron thiazole synthesis Cope elimination Cope rearrangement Corey reagent Corey–Fuchs reaction Corey–Gilman–Ganem oxidation Corey–Kim oxidation Corey-Nicolaou macrolactonization Corey–Posner, Whitesides–House reaction Corey-Seebach reaction Corey–Winter olefin synthesis Corey–Winter reaction Cornforth rearrangement Coupling reaction Crabbé reaction Craig method Cram's rule of asymmetric induction Creighton process Criegee reaction Criegee rearrangement Cross metathesis Crum Brown–Gibson rule Curtius degradation Curtius rearrangement, Curtius reaction Cyanohydrin reaction
== History == SR-17018 was patented in 2016 and first described in the scientific literature by Laura Bohn and colleagues at the Scripps Research Institute in Jupiter, Florida in 2017. The drug was encountered as a novel designer drug online by 2023. Analogues like brorphine and SR-14968 have also been encountered as novel designer drugs. Brorphine is said to not be popular among recreational users as it produces little euphoria but reportedly still has potential for severe respiratory depression. In 2024, discussion of SR-17018 on the social media website Reddit suddenly dramatically increased and the drug emerged as an informal treatment for opioid discontinuation and withdrawal. On July 1, 2026, the United States Drug Enforcement Administration (DEA) signed a letter of intent to temporarily place SR-17018 under Schedule I of the Controlled Substances Act. This will likely take effect on July 31, 2026. There has been opposition to the announcement, for instance by the Students for Sensible Drug Policy (SSDP).
Civilians returned to power in 1985 when José Sarney assumed the presidency. He became unpopular during his tenure through failure to control the economic crisis and hyperinflation he inherited from the military regime. Sarney's unsuccessful government led to the election in 1989 of the almost-unknown Fernando Collor, who was subsequently impeached by the National Congress in 1992. Collor was succeeded by his vice-president, Itamar Franco, who appointed Fernando Henrique Cardoso as Minister of Finance. In 1994, Cardoso devised a highly successful Plano Real that, after decades of failed economic plans made by previous governments attempting to curb hyperinflation, finally stabilized the Brazilian economy. Cardoso won the 1994 election, and again in 1998.
Sources: en.wikipedia.org
The common death adder (Acanthophis antarcticus) is a highly venomous snake species with a 50–60% untreated mortality rate. It is also the fastest striking venomous snake in the world. A death adder can go from a strike position, to strike and envenoming their prey, and back to strike position again, in less than 0.15 seconds. The SC LD50 value is 0.4 mg/kg and the venom yield per bite can range anywhere from 70–236 mg. Unlike other snakes that flee from approaching humans crashing through the undergrowth, common death adders are more likely to sit tight and risk being stepped on, making them more dangerous to the unwary bushwalker. They are said to be reluctant to bite unless actually touched.
Major Force reappears in Battle for Blüdhaven, a series set a year after the events of Infinite Crisis, as the leader of project S.H.A.D.E. In issue #5, Major Force brutally beats Outsiders member Major Victory and rips off his right arm. He also picks a fight with Hal Jordan, having vowed to kill Green Lanterns on sight after his last encounter with Kyle Rayner. Captain Atom drains Major Force of his energy, leaving him a deflated husk. Major Force is later seen reconstituted and a part of a new regiment of S.H.A.D.E. soldiers. A battle ensues with Uncle Sam and the Freedom Fighters for the soul of America, wherein Major Force is quickly dispatched by Miss America. Major Force later appears as a member of the Secret Society during the wedding of Green Arrow and Black Canary.
== Occurrence, other == Methylglyoxal is a component of some kinds of honey, including manuka honey; it appears to have activity against E. coli and S. aureus and may help prevent formation of biofilms formed by P. aeruginosa. Research suggests that methylglyoxal contained in honey does not cause an increased formation of advanced glycation end products (AGEs) in healthy persons.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.